In conclusion, our in vitro, in silico and in vivo results clearly demonstrated the therapeutic efficacy of novel HMG-CoA reductase inhibitor (F18-n-Octadecanyl-O-α-D-glucopyranosyl(6′ → 1′′)-O-α-D-glucopyranoside) over statins as a substitute against hyperlipidemia. Here, HMGCR is linked to hyperlipidemia.